Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B M Ewenstein

Showing results (1-10 of 75) with videos related to

Pageof 8
Sort By:
The New England Journal of Medicine|November 14, 1997
Antithrombotic agents and thromboembolic diseaseB M Ewenstein
Annual Review of Medicine|January 1, 1997
Von Willebrand's diseaseB M Ewenstein
American Journal of Obstetrics and Gynecology|September 1, 1996
The pathophysiology of bleeding disorders presenting as abnormal uterine bleedingB M Ewenstein
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 10, 2001
Use of ristocetin cofactor activity in the management of von Willebrand diseaseB M Ewenstein
Thrombosis and Haemostasis|November 1, 2001
Continuous infusion of recombinant factor VIIa: continue or not?B M Ewenstein
Thrombosis and Haemostasis|January 31, 2002
Regulated secretion in endothelial cells: biology and clinical implicationsY H Datta, B M Ewenstein
The Journal of Pediatrics|April 1, 1997
Recombinant factor VIII: are we really getting more for less?J B Gorlin, B M Ewenstein
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 15, 2011
Re: low incidence of factor VIII inhibitors in PUPs during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical studyB M Ewenstein, A J Reininger
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 26, 2009
Bypassing agent prophylaxis for preventing arthropathy in patients with inhibitorsB M Ewenstein, W-Y Wong, A Schoppmann
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 31, 2001
Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North AmericaA J Cohen, C M Kessler, B M Ewenstein, et al.
Pageof 8

Showing results (1-10 of 75) with videos related to

Sort By:
Pageof 8
The New England Journal of Medicine|November 14, 1997
Antithrombotic agents and thromboembolic diseaseB M Ewenstein
Annual Review of Medicine|January 1, 1997
Von Willebrand's diseaseB M Ewenstein
American Journal of Obstetrics and Gynecology|September 1, 1996
The pathophysiology of bleeding disorders presenting as abnormal uterine bleedingB M Ewenstein
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 10, 2001
Use of ristocetin cofactor activity in the management of von Willebrand diseaseB M Ewenstein
Thrombosis and Haemostasis|November 1, 2001
Continuous infusion of recombinant factor VIIa: continue or not?B M Ewenstein
Thrombosis and Haemostasis|January 31, 2002
Regulated secretion in endothelial cells: biology and clinical implicationsY H Datta, B M Ewenstein
The Journal of Pediatrics|April 1, 1997
Recombinant factor VIII: are we really getting more for less?J B Gorlin, B M Ewenstein
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 15, 2011
Re: low incidence of factor VIII inhibitors in PUPs during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical studyB M Ewenstein, A J Reininger
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 26, 2009
Bypassing agent prophylaxis for preventing arthropathy in patients with inhibitorsB M Ewenstein, W-Y Wong, A Schoppmann
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 31, 2001
Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North AmericaA J Cohen, C M Kessler, B M Ewenstein, et al.
Pageof 8